Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma
Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin sulphate proteoglycan (CSPG) on cutaneous melanoma cells. Here, we compare the B5-staining of CSPG in...
Gespeichert in:
Veröffentlicht in: | Annals of oncology 2006-12, Vol.17 (12), p.1830-1834 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1834 |
---|---|
container_issue | 12 |
container_start_page | 1830 |
container_title | Annals of oncology |
container_volume | 17 |
creator | Kiewe, P Bechrakis, NE Schmittel, A Ruf, P Lindhofer, H Thiel, E Nagorsen, D |
description | Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin sulphate proteoglycan (CSPG) on cutaneous melanoma cells. Here, we compare the B5-staining of CSPG in primaries and metastases of uveal melanoma. Material and methods: Immunohistopathological staining was performed in 15 cutaneous and 39 uveal melanoma samples. A score for intracellular and surface staining was established. B5 staining was compared in primaries and metastases of uveal melanoma using Student's t-test. Results: Eight of 11 (73%) uveal melanoma metastases were positive for B5-staining whereas only 5 of 28 (18%) primary uveal melanoma samples were B5-positive (P < 0.001). Nine of 15 cutaneous melanoma samples (60%) were B5-positive without significant difference between primary and metastatic lesions. Surface staining was found both on uveal melanoma metastases and cutaneous melanomas. Conclusions: CSPG was expressed significantly more often in metastases than in primaries of uveal melanoma. It potentially may be one factor associated with metastatic spread. Further studies are needed to determine its use as prognostic factor. The mAbB5 may also be a promising tool for immunotherapy due to its strong staining of CSPG on the surface of cutaneous and metastatic uveal melanoma cells. |
doi_str_mv | 10.1093/annonc/mdl305 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68226963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68226963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-4711db9b84de8051588b3f56b9d555f27ff6329968f7d3112a7be40f4de38a923</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYModq0--iqDoNiHsfmYfD1q0bZQqg-Kiy8hk0lsaiZZk0zp_vdGdnGhEAjk_u69J-cA8BLB9whKcqpjTNGczlMgkD4CK0SZ7AUc0GOwghKTnlMyHIFnpdxCCJnE8ik4QkxyxBhZgXAZTba62KkzNylOOfnqY1eWsLnR1XabnKpNv8LW6NjZ-022pfgUu3cfaefneYmpdZvq73zdnnStc7ZVl3Zs6ZLrljurQ3sLOqZZPwdPnA7Fvtjfx-D750_fzi76qy_nl2cfrnozYFr7gSM0jXIUw2QFpIgKMRJH2SgnSqnD3DlGsJRMOD4RhLDmox2gazgRuv35GLzdzW3q_yy2VDX7YmxoKmxaimICYyYZaeDrB-BtWnJs2hSSjGHOuGhQv4NMTqVk69Qm-1nnrUJQ_ctA7TJQuwwa_2o_dBlnOx3ovekNeLMHdDE6uKyj8eXAieaCEOiw2Jdq7__Xdf6tGCecqov1T8UYg-vrr2v1g_wFPKWhvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196627678</pqid></control><display><type>article</type><title>Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kiewe, P ; Bechrakis, NE ; Schmittel, A ; Ruf, P ; Lindhofer, H ; Thiel, E ; Nagorsen, D</creator><creatorcontrib>Kiewe, P ; Bechrakis, NE ; Schmittel, A ; Ruf, P ; Lindhofer, H ; Thiel, E ; Nagorsen, D</creatorcontrib><description>Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin sulphate proteoglycan (CSPG) on cutaneous melanoma cells. Here, we compare the B5-staining of CSPG in primaries and metastases of uveal melanoma. Material and methods: Immunohistopathological staining was performed in 15 cutaneous and 39 uveal melanoma samples. A score for intracellular and surface staining was established. B5 staining was compared in primaries and metastases of uveal melanoma using Student's t-test. Results: Eight of 11 (73%) uveal melanoma metastases were positive for B5-staining whereas only 5 of 28 (18%) primary uveal melanoma samples were B5-positive (P < 0.001). Nine of 15 cutaneous melanoma samples (60%) were B5-positive without significant difference between primary and metastatic lesions. Surface staining was found both on uveal melanoma metastases and cutaneous melanomas. Conclusions: CSPG was expressed significantly more often in metastases than in primaries of uveal melanoma. It potentially may be one factor associated with metastatic spread. Further studies are needed to determine its use as prognostic factor. The mAbB5 may also be a promising tool for immunotherapy due to its strong staining of CSPG on the surface of cutaneous and metastatic uveal melanoma cells.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdl305</identifier><identifier>PMID: 16971663</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Chondroitin Sulfate Proteoglycans - metabolism ; chondroitin sulphate proteoglycan ; Dermatology ; Humans ; Immunohistochemistry ; immunotherapy ; Medical sciences ; Melanoma - metabolism ; Melanoma - pathology ; Neoplasm Metastasis ; ocular melanoma ; Ophthalmology ; Pharmacology. Drug treatments ; Tumors and pseudotumors of the eye, orbit, eyelid, lacrimal apparatus ; Tumors of the skin and soft tissue. Premalignant lesions ; uveal melanoma ; Uveal Neoplasms - metabolism ; Uveal Neoplasms - pathology</subject><ispartof>Annals of oncology, 2006-12, Vol.17 (12), p.1830-1834</ispartof><rights>2007 INIST-CNRS</rights><rights>Copyright Springer Science & Business Media Dec 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-4711db9b84de8051588b3f56b9d555f27ff6329968f7d3112a7be40f4de38a923</citedby><cites>FETCH-LOGICAL-c425t-4711db9b84de8051588b3f56b9d555f27ff6329968f7d3112a7be40f4de38a923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18425881$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16971663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kiewe, P</creatorcontrib><creatorcontrib>Bechrakis, NE</creatorcontrib><creatorcontrib>Schmittel, A</creatorcontrib><creatorcontrib>Ruf, P</creatorcontrib><creatorcontrib>Lindhofer, H</creatorcontrib><creatorcontrib>Thiel, E</creatorcontrib><creatorcontrib>Nagorsen, D</creatorcontrib><title>Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin sulphate proteoglycan (CSPG) on cutaneous melanoma cells. Here, we compare the B5-staining of CSPG in primaries and metastases of uveal melanoma. Material and methods: Immunohistopathological staining was performed in 15 cutaneous and 39 uveal melanoma samples. A score for intracellular and surface staining was established. B5 staining was compared in primaries and metastases of uveal melanoma using Student's t-test. Results: Eight of 11 (73%) uveal melanoma metastases were positive for B5-staining whereas only 5 of 28 (18%) primary uveal melanoma samples were B5-positive (P < 0.001). Nine of 15 cutaneous melanoma samples (60%) were B5-positive without significant difference between primary and metastatic lesions. Surface staining was found both on uveal melanoma metastases and cutaneous melanomas. Conclusions: CSPG was expressed significantly more often in metastases than in primaries of uveal melanoma. It potentially may be one factor associated with metastatic spread. Further studies are needed to determine its use as prognostic factor. The mAbB5 may also be a promising tool for immunotherapy due to its strong staining of CSPG on the surface of cutaneous and metastatic uveal melanoma cells.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chondroitin Sulfate Proteoglycans - metabolism</subject><subject>chondroitin sulphate proteoglycan</subject><subject>Dermatology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>immunotherapy</subject><subject>Medical sciences</subject><subject>Melanoma - metabolism</subject><subject>Melanoma - pathology</subject><subject>Neoplasm Metastasis</subject><subject>ocular melanoma</subject><subject>Ophthalmology</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumors and pseudotumors of the eye, orbit, eyelid, lacrimal apparatus</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>uveal melanoma</subject><subject>Uveal Neoplasms - metabolism</subject><subject>Uveal Neoplasms - pathology</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd1rFDEUxYModq0--iqDoNiHsfmYfD1q0bZQqg-Kiy8hk0lsaiZZk0zp_vdGdnGhEAjk_u69J-cA8BLB9whKcqpjTNGczlMgkD4CK0SZ7AUc0GOwghKTnlMyHIFnpdxCCJnE8ik4QkxyxBhZgXAZTba62KkzNylOOfnqY1eWsLnR1XabnKpNv8LW6NjZ-022pfgUu3cfaefneYmpdZvq73zdnnStc7ZVl3Zs6ZLrljurQ3sLOqZZPwdPnA7Fvtjfx-D750_fzi76qy_nl2cfrnozYFr7gSM0jXIUw2QFpIgKMRJH2SgnSqnD3DlGsJRMOD4RhLDmox2gazgRuv35GLzdzW3q_yy2VDX7YmxoKmxaimICYyYZaeDrB-BtWnJs2hSSjGHOuGhQv4NMTqVk69Qm-1nnrUJQ_ctA7TJQuwwa_2o_dBlnOx3ovekNeLMHdDE6uKyj8eXAieaCEOiw2Jdq7__Xdf6tGCecqov1T8UYg-vrr2v1g_wFPKWhvw</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Kiewe, P</creator><creator>Bechrakis, NE</creator><creator>Schmittel, A</creator><creator>Ruf, P</creator><creator>Lindhofer, H</creator><creator>Thiel, E</creator><creator>Nagorsen, D</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma</title><author>Kiewe, P ; Bechrakis, NE ; Schmittel, A ; Ruf, P ; Lindhofer, H ; Thiel, E ; Nagorsen, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-4711db9b84de8051588b3f56b9d555f27ff6329968f7d3112a7be40f4de38a923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chondroitin Sulfate Proteoglycans - metabolism</topic><topic>chondroitin sulphate proteoglycan</topic><topic>Dermatology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>immunotherapy</topic><topic>Medical sciences</topic><topic>Melanoma - metabolism</topic><topic>Melanoma - pathology</topic><topic>Neoplasm Metastasis</topic><topic>ocular melanoma</topic><topic>Ophthalmology</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumors and pseudotumors of the eye, orbit, eyelid, lacrimal apparatus</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>uveal melanoma</topic><topic>Uveal Neoplasms - metabolism</topic><topic>Uveal Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kiewe, P</creatorcontrib><creatorcontrib>Bechrakis, NE</creatorcontrib><creatorcontrib>Schmittel, A</creatorcontrib><creatorcontrib>Ruf, P</creatorcontrib><creatorcontrib>Lindhofer, H</creatorcontrib><creatorcontrib>Thiel, E</creatorcontrib><creatorcontrib>Nagorsen, D</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kiewe, P</au><au>Bechrakis, NE</au><au>Schmittel, A</au><au>Ruf, P</au><au>Lindhofer, H</au><au>Thiel, E</au><au>Nagorsen, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>17</volume><issue>12</issue><spage>1830</spage><epage>1834</epage><pages>1830-1834</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Metastatic uveal melanoma has a poor prognosis and limited therapeutic options. Proteoglycans are involved in tumor cell invasion and metastatic behavior. The mAbB5 stains a chondroitin sulphate proteoglycan (CSPG) on cutaneous melanoma cells. Here, we compare the B5-staining of CSPG in primaries and metastases of uveal melanoma. Material and methods: Immunohistopathological staining was performed in 15 cutaneous and 39 uveal melanoma samples. A score for intracellular and surface staining was established. B5 staining was compared in primaries and metastases of uveal melanoma using Student's t-test. Results: Eight of 11 (73%) uveal melanoma metastases were positive for B5-staining whereas only 5 of 28 (18%) primary uveal melanoma samples were B5-positive (P < 0.001). Nine of 15 cutaneous melanoma samples (60%) were B5-positive without significant difference between primary and metastatic lesions. Surface staining was found both on uveal melanoma metastases and cutaneous melanomas. Conclusions: CSPG was expressed significantly more often in metastases than in primaries of uveal melanoma. It potentially may be one factor associated with metastatic spread. Further studies are needed to determine its use as prognostic factor. The mAbB5 may also be a promising tool for immunotherapy due to its strong staining of CSPG on the surface of cutaneous and metastatic uveal melanoma cells.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16971663</pmid><doi>10.1093/annonc/mdl305</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0923-7534 |
ispartof | Annals of oncology, 2006-12, Vol.17 (12), p.1830-1834 |
issn | 0923-7534 1569-8041 |
language | eng |
recordid | cdi_proquest_miscellaneous_68226963 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Antineoplastic agents Biological and medical sciences Chondroitin Sulfate Proteoglycans - metabolism chondroitin sulphate proteoglycan Dermatology Humans Immunohistochemistry immunotherapy Medical sciences Melanoma - metabolism Melanoma - pathology Neoplasm Metastasis ocular melanoma Ophthalmology Pharmacology. Drug treatments Tumors and pseudotumors of the eye, orbit, eyelid, lacrimal apparatus Tumors of the skin and soft tissue. Premalignant lesions uveal melanoma Uveal Neoplasms - metabolism Uveal Neoplasms - pathology |
title | Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A12%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20chondroitin%20sulphate%20proteoglycan%20expression%20(B5%20immunoreactivity)%20in%20metastases%20of%20uveal%20melanoma&rft.jtitle=Annals%20of%20oncology&rft.au=Kiewe,%20P&rft.date=2006-12-01&rft.volume=17&rft.issue=12&rft.spage=1830&rft.epage=1834&rft.pages=1830-1834&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdl305&rft_dat=%3Cproquest_cross%3E68226963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196627678&rft_id=info:pmid/16971663&rfr_iscdi=true |